Implantable cardiac defibrillators

Medical Clinics of North America

Volumn 85, Issue 2, 2001, Pages 343-367

  Peters, Robert W ^a,b   Gold, Michael R ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYCARDIA; COMPUTER MEMORY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; DEFIBRILLATOR; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART PACING; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMATOMA; HUMAN; IMPLANTATION; PACEMAKER ELECTRODE; PRIORITY JOURNAL; PROSTHESIS FAILURE; REVIEW; SENSOR;

EID: 0035114208     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70319-9     Document Type: Article

References (52)

1. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
2. The pacemaker syndrome
3. Implantable transvenous cardioverter-defibrillators
4. The Sudden Cardiac Death in Heart Failure Trial: Pilot study
5. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases
6. Permanent pacemaker and implantable cardioverter-defibrillator implantation
7. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery
8. A randomized study of the prevention of sudden death in patients with coronary artery disease
9. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations. CAMIAT
10. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
11. Cardiomyopathy trial
12. Mechanism of cardiac defibrillation: A different point of view
13. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone
14. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized controlled trials
15. Prevention of bacterial endocarditis: Recommendations by the American Heart Association
16. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
17. Clinical characteristics and outcome of patients with high defibrillation thresholds: A multicenter study
18. Personal and public safety issues related to arrhythmias that may affect consciousness: Implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society for Pacing and Electrophysiology
19. Sudden coronary death in the United States: 1980-1985
20. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system
21. Complications associated with pectoral cardioverter-defibrillator implantation: Comparison of subcutaneous and submuscular approaches
22. Clinical results with nonthoracotomy ICD systems
23. International Mexiletine and Placebo Antiarrhythmic Coronary Trial
24. Anatomical and morphological evaluation of pacemaker lead compression
25. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. EMIAT
26. Michel Mirowski and the implantable cardioverter-defibrillator
27. Hospitalization charges in the Antiarrhythmics versus Implantable Defibrillator (AVID) Trial. The AVID Economic Analysis study
28. Implantable transvenous cardioverter defibrillator leads: The dark side
29. New method for terminating cardiac arrhythmias: Use of synchronized capacity discharge
30. Benefits and lessons learned from stored electrogram information in implantable defibrillators
31. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia
32. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT
33. Antiarrhythmic drug-implantable cardioverter-defibrillator interactions
34. The Cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation
35. Inappropriate shocks from implanted cardioverter defibrillators caused by sensing of diaphragmatic myopotentials
36. Long-term management of recurrent tachycardia by cardiac burst pacing
37. Implantable cardioverter-defibrillators
38. Italian multicenter clinical experience with endocardial defibrillation: Acute and long-term results in 307 patients
39. Postoperative lead-related complications in patients with non-thoracotomy defibrillation lead systems
40. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg)
41. Defibrillation threshold: Clinical utility and therapeutic implications
42. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
43. Experience with two different nonthoracotomy systems for implantable defibrillator in 170 patients
44. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
45. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking?
46. Mechanisms of defibrillation for monophasic and biphasic waveforms
47. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
48. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors: A randomized study
49. Appropriate use of the implantable cardioverter defibrillator: A Canadian perspective
50. A permanent transvenous lead system for an implantable pacemaker cardioverter-defibrillator
51. Results of the international study of the implantable cardioverter-defibrillator: A comparison of epicardial and endocardial lead systems
52. Termination of ventricular fibrillation in man by externally applied countershock